What changed from existing technology?
This study looked at whether stopping certain arthritis medications before a COVID-19 booster shot made the vaccine work better, and if stopping the medications made arthritis worse.
This is the first study to examine the effect of temporarily stopping biologic or targeted synthetic DMARDs around the time of a COVID-19 supplemental dose vaccination on immunogenicity and disease activity in inflammatory arthritis patients.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
d COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis. Importance The COVID-19 pandemic disproportionately affected pati
Title ↗OpenAlex author affiliations: LabCorp (United States)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This study may inform clinical guidelines on managing immunomodulatory medications around the time of COVID-19 vaccination in patients with inflammatory arthritis.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchTemporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory ArthritisJAMA Internal Medicine · Published 2026-10-05 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.